CSS
ATNM icon

Cubist Systematic Strategies’s Actinium Pharmaceuticals ATNM Stock Holding History

Cubist Systematic Strategies’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2 Sell
1
-1,926
-100% -$3.14K ﹤0.01% 2947
2025
Q2 		$2.7K Buy
+1,927
New +$2.88K ﹤0.01% 2869
2023
Q1 		– Sell
-34,298
Closed -$365K – 3887
2022
Q4 		$365K Buy
+34,298
New +$348K ﹤0.01% 3235
2022
Q3 		– Sell
-31,484
Closed -$151K – 4411
2022
Q2 		$151K Buy
+31,484
New +$179K ﹤0.01% 3814

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cubist Systematic Strategies's ATNM Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Actinium Pharmaceuticals (ATNM) stake by 100% in Q3 2025, selling an estimated $3.14K and leaving 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #2947.

Cubist Systematic Strategies first reported a position in ATNM in Q2 2022 and has held it in 4 quarters since. The position peaked at $365K in Q4 2022. 61 funds tracked by Wall St. Rank hold ATNM as of Q3 2025.

  • Cubist Systematic Strategies held 1 share of Actinium Pharmaceuticals worth $2 as of Q3 2025.
  • Cubist Systematic Strategies sold 1,926 Actinium Pharmaceuticals shares in Q3 2025, an estimated $3.14K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2947 holding.
  • Cubist Systematic Strategies first reported a position in Actinium Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
  • Cubist Systematic Strategies's Actinium Pharmaceuticals position peaked at $365K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.